Lu Hongbo

Director · Zenas BioPharma, Inc.

Every open-market stock purchase Lu Hongbo has reported to the SEC on Form 4 that met our signal bar, parsed straight from the filings. This page tracks where those buys landed inside insider clusters and how the prices paid compare to where the stock trades now.

Total bought
$14.1M
Open-market buys
7
Companies
2
Last buy
Mar 31, 2026

Where the buys stand today

  • ZBIO
    Zenas BioPharma, Inc.
    +48.5% vs price paid

    5 purchases totalling $9.1M at an average of $18.86 per share; the stock last traded at $28.00. See all insider buying in ZBIO →

    Avg price paid
    $18.86
    Latest price
    $28.00
    Market cap
    $1.8B
  • TERN
    Terns Pharmaceuticals, Inc.

    2 purchases totalling $5.0M at an average of $10.50 per share. See all insider buying in TERN →

    Avg price paid
    $10.50
    Latest price
    —
    Market cap
    $6.1B

Cluster participation

Qualifying buys grouped with other insiders buying the same stock — the pattern this site exists to catch.

All reported buys

DateTickerSharesPriceValueFiling
Mar 31, 2026
ZBIOcluster
75,000$20.00$1.5MSEC ↗
Feb 11, 2026
ZBIOcluster
25,985$22.50$584.7KSEC ↗
Oct 7, 2025
ZBIOcluster
263,160$19.00$5.0MSEC ↗
Sep 13, 2024
ZBIOcluster
58,823$17.00$1.0MSEC ↗
Sep 13, 2024
ZBIOcluster
58,823$17.00$1.0MSEC ↗
Sep 12, 2024
TERNcluster
190,476$10.50$2.0MSEC ↗
Sep 12, 2024
TERNcluster
285,714$10.50$3.0MSEC ↗

Follow new qualifying clusters involving Lu Hongbo or other insiders

Explore qualifying clusters from public SEC filings. Pro adds email and Telegram notifications after detection.

About this data

Figures are parsed from Lu Hongbo's Form 4 filings on SEC EDGAR (CIK 1767584) and cover open-market purchases (transaction code P) — grants, option exercises, and sales are excluded, which is why totals here can differ from raw filing counts. Every row links to its source document.

This page is informational and reflects public filing data. It is not investment advice.